Interleukin 15 (IL15) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 15 (IL15) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 (IL15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15)

The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 15 (IL15) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 15 (IL15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 15 (IL15) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

ARMO Biosciences Inc

Calypso Biotech SA

Novartis AG

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 15 (IL15) Overview 6

Therapeutics Development 7

Interleukin 15 (IL15) - Products under Development by Stage of Development 7

Interleukin 15 (IL15) - Products under Development by Therapy Area 8

Interleukin 15 (IL15) - Products under Development by Indication 9

Interleukin 15 (IL15) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 15 (IL15) - Products under Development by Companies 12

Interleukin 15 (IL15) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interleukin 15 (IL15) - Companies Involved in Therapeutics Development 21

Amgen Inc 21

ARMO Biosciences Inc 22

Calypso Biotech SA 23

Novartis AG 24

ZIOPHARM Oncology Inc 25

Interleukin 15 (IL15) - Drug Profiles 26

AM-0015 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AMG-714 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

ASN-006 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BNZ-1 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BNZ-2 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CALY-002 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Cellular Immunotherapy for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NIZ-985 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Interleukin 15 (IL15) - Dormant Projects 35

Interleukin 15 (IL15) - Discontinued Products 36

Interleukin 15 (IL15) - Featured News & Press Releases 37

May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 37

Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 37

Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 38

Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 39

Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy 39

Dec 15, 2006: Genmab Announces AMG 714 Development Update 40

May 16, 2006: AMG 714 Data To Be Presented At Eular Conference 40

Mar 10, 2006: Genmab Announces Update On AMG 714 Program With Amgen 40

Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data 41

Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15 41

Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis 41

Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis 42

Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Amgen Inc, H2 2016 21

Pipeline by ARMO Biosciences Inc, H2 2016 22

Pipeline by Calypso Biotech SA, H2 2016 23

Pipeline by Novartis AG, H2 2016 24

Pipeline by ZIOPHARM Oncology Inc, H2 2016 25

Dormant Projects, H2 2016 35

Discontinued Products, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports